Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment being planned by the Trump administration.
Under the proposed plan, state Medicaid programs and Medicare Part D insurance plans will be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro and Zepbound for patients for “weight management” purposes, according to Centers for Medicare and Medicaid Services documents obtained by The Washington Post.
It’s a strong signal that the administration is open to more broadly covering GLP-1 drugs — lauded by many as a miracle solution to Americans’ long-standing struggle with weight — through government insurance programs. Medicare covers the drugs mainly for patients with Type 2 diabetes, even as some private insurance plans cover them for patients with obesity.
Medicare, Medicaid Plans To Experiment With Covering Weight Loss Drugs – @washingtonpost https://t.co/ctAu2B9pX5
— LiveSquawk (@LiveSquawk) August 1, 2025
